10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and…
5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and…
Race Oncology Limited is pleased to announce that Professor Borje S. Andersson has agreed to join Race as Chief Medical Officer and Executive Director. Under this role, Prof. Andersson will…
Race Oncology is pleased to announce that it has appointed the clinical and regulatory strategy advisor, CCS Associates (CCSA, California, USA) to advise on development options for Bisantrene as an…
Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology. https://youtu.be/ebXA6rD5pRs
